Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NanoViricides, a nano-biopharmaceutical company, has recently submitted a grant application to the US Department of Defense. This grant, if awarded, will be used for the development of broad-spectrum nanoviricides drugs.
Subscribe to our email newsletter
If successful, a broad-spectrum nanoviricide could be employed as an important Medical CounterMeasure against bio-terrorism and emerging infectious diseases such as Ebola or Marburg, and dengue.
The company has already demonstrated that some of the nanoviricides it has created are broad-spectrum. It is believed that viruses are unlikely to escape such broad-spectrum nanoviricides by mutation because such mutations would also cause a loss of infectivity.
The company said that it has assembled a team comprising several renowned institutions and companies for the proposed project. There is no guarantee that the grant application will result in any funding.